Efficacy of Tranexamic Acid in Reducing Myomectomy Associated Blood Loss in Federal Teaching Hospital Abakaliki.

Efficacy of Tranexamic Acid in Reducing Myomectomy Associated Blood Loss in Federal Teaching Hospital Abakaliki

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04560465

Acronym

AEFUTHA

Enrollment

Registered

2020-09-23

Start date

2018-06-01

Completion date

2019-06-01

Last updated

2020-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To Determine Efficacy of Tranexamic Acid in Reducing Blood Loss During Myomectomy

Keywords

Tranexamic acid, Myomectomy, Blood loss, Gravimetric

Brief summary

to determine safety and efficacy of Tranexamic Acid in reducing blood loss during Myomectomy in our institution.

Detailed description

A double blinded randomized controlled trial in which cases were given 1000mg intravenous tranexamic acid into 1L of intravenous normal saline and control were given 10mls of placebo water for injection into same amount of intravenous fluid. outcome of both groups in terms of intraoperative blood loss, duration of surgery, postoperative packed cell volume and total blood loss with risk of blood transfusion were then determined.

Interventions

DRUGTranexamic acid

intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Masking description

double blind

Intervention model description

two groups comprising of cases and control

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* non-pregnant women with symptomatic myomas women with no known contraindication to tranexamic acid

Exclusion criteria

* past history of thromboembolic disorder, ischaemic heart disease, malignancy or liver disease

Design outcomes

Primary

Measure	Time frame	Description
Average duration of surgery in each group	one year	Average duration of Surgeries were calculated for each group
Mean intraoperative Blood loss	one year	The mean intraoperative blood loss was calculated for both groups
Postoperative Haemoglobin concentration	one year	Average Postoperative Haemoglobin concentration of both groups were determined

Secondary

Measure	Time frame	Description
Blood Transfusion	One year	Risk of Blood Transfusion of both groups were determined

Countries

Nigeria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026